CHOP's Zev Sunleaf reveals that ensuring a partner has the capability and commitment to develop a technology is a more difficult negotiation point than the financial details. This prioritizes patient impact and long-term success over immediate revenue, a key insight for dealmakers.
Zev Sunleaf simplifies the complex process of technology transfer by calling it "matchmaking." This re-frames the goal from a purely transactional one to finding the right strategic partner—be it investors or companies—to advance research from the lab bench to the patient's bedside.
Zev Sunleaf, VP of Tech Transfer at CHOP, entered the field with a business degree, not a science Ph.D. His experience co-founding startups based on university research provided the necessary expertise, demonstrating an alternative, entrepreneurial route into a traditionally science-heavy profession.
The "Baby KJ" case, a therapeutic for one child, shows that non-commercial projects can deliver significant value. Its success strengthened relationships with D.C. policymakers, boosted NIH support for basic research, and showcased the ecosystem's power, creating a positive ripple effect for the entire industry.
CHOP's tech transfer function is twofold. It not only licenses its own discoveries ("outbound") but also facilitates collaborations where companies leverage CHOP's expertise for their existing pipelines ("inbound"). This positions the research institution as both an IP source and a strategic research partner.
Zev Sunleaf advises active participation in industry groups not just for networking, but for serendipitous problem-solving. By attending a casual event, he found a company that could build a specific AI tool he had sought for years, illustrating how "showing up" can lead to direct, tangible business outcomes.